Raymond James Trims Teva Pharmaceutical Industries (NYSE:TEVA) Target Price to $15.00

Teva Pharmaceutical Industries (NYSE:TEVA) had its target price trimmed by Raymond James from $22.00 to $15.00 in a report published on Thursday morning, The Fly reports. The brokerage currently has an outperform rating on the stock.

Other equities analysts have also recently issued research reports about the company. Royal Bank of Canada set a $19.00 price target on Teva Pharmaceutical Industries and gave the company a hold rating in a report on Friday, May 3rd. UBS Group cut Teva Pharmaceutical Industries from a buy rating to a neutral rating and dropped their target price for the stock from $22.00 to $12.00 in a report on Tuesday, May 28th. Mizuho set a $11.00 target price on Teva Pharmaceutical Industries and gave the stock a hold rating in a report on Monday, June 17th. Sanford C. Bernstein dropped their target price on Teva Pharmaceutical Industries from $17.00 to $11.00 and set a market perform rating for the company in a report on Tuesday, June 18th. They noted that the move was a valuation call. Finally, Argus raised Teva Pharmaceutical Industries from a hold rating to a buy rating and set a $12.00 target price for the company in a report on Friday, July 5th. Six investment analysts have rated the stock with a sell rating, fourteen have given a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. The company has a consensus rating of Hold and an average target price of $13.21.

Teva Pharmaceutical Industries stock traded down $0.27 during trading hours on Thursday, hitting $7.02. The stock had a trading volume of 19,402,224 shares, compared to its average volume of 22,598,402. The company’s 50-day simple moving average is $8.40. The company has a debt-to-equity ratio of 1.73, a quick ratio of 0.62 and a current ratio of 0.96. The stock has a market cap of $7.41 billion, a P/E ratio of 2.51, a PEG ratio of 0.76 and a beta of 1.64. Teva Pharmaceutical Industries has a fifty-two week low of $6.34 and a fifty-two week high of $25.96.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings results on Wednesday, August 7th. The company reported $0.57 EPS for the quarter, beating the consensus estimate of $0.55 by $0.02. The firm had revenue of $4.34 billion during the quarter, compared to analysts’ expectations of $4.25 billion. Teva Pharmaceutical Industries had a positive return on equity of 16.04% and a negative net margin of 21.94%. The company’s revenue for the quarter was down 7.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.78 EPS. On average, equities analysts anticipate that Teva Pharmaceutical Industries will post 2.26 earnings per share for the current fiscal year.

In other Teva Pharmaceutical Industries news, Director Sol J. Barer purchased 111,000 shares of the company’s stock in a transaction that occurred on Monday, June 3rd. The stock was purchased at an average cost of $8.98 per share, with a total value of $996,780.00. Following the acquisition, the director now directly owns 115,942 shares of the company’s stock, valued at approximately $1,041,159.16. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Also, VP Notaristefani Carlo De sold 16,070 shares of the firm’s stock in a transaction on Monday, May 20th. The shares were sold at an average price of $11.42, for a total value of $183,519.40. Following the sale, the vice president now directly owns 49,659 shares of the company’s stock, valued at $567,105.78. The disclosure for this sale can be found here. Company insiders own 0.49% of the company’s stock.

Hedge funds have recently added to or reduced their stakes in the stock. First Interstate Bank bought a new position in Teva Pharmaceutical Industries in the 2nd quarter valued at $28,000. Kavar Capital Partners LLC bought a new position in Teva Pharmaceutical Industries in the 2nd quarter valued at $35,000. G&S Capital LLC boosted its position in Teva Pharmaceutical Industries by 99.4% in the 2nd quarter. G&S Capital LLC now owns 4,012 shares of the company’s stock valued at $37,000 after buying an additional 2,000 shares during the last quarter. Lindbrook Capital LLC boosted its position in Teva Pharmaceutical Industries by 61.2% in the 1st quarter. Lindbrook Capital LLC now owns 2,489 shares of the company’s stock valued at $39,000 after buying an additional 945 shares during the last quarter. Finally, NEXT Financial Group Inc boosted its position in Teva Pharmaceutical Industries by 384.8% in the 2nd quarter. NEXT Financial Group Inc now owns 4,276 shares of the company’s stock valued at $39,000 after buying an additional 3,394 shares during the last quarter. 65.69% of the stock is owned by hedge funds and other institutional investors.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

See Also: Equity Income

The Fly

Analyst Recommendations for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.